CoChat

Preclinical Pharmacokinetics and Interspecies Scaling of a Novel Vitronectin Receptor Antagonist

Ward, Keith W., Azzarano, Leonard M., Bondinell, William E., Cousins, Russell D., Huffman, William F., Jakas, Dalia R., Keenan, Richard M., Ku, Thomas W., Lundberg, Dave, Miller, William H., Mumaw, Jayme A., Newlander, Kenneth A., Pirhalla, Jill L., Roethke, Theresa J., Salyers, Kevin L., Souder, Pamela R., Stelman, Gary J., Smith, Brian R. · 1999 · Drug Metabolism and Disposition
Cited by 39

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Allometric scaling may be used in drug development to predict the pharmacokinetics of xenobiotics in humans from animal data. Although allometry may be successful for compounds that are excreted unchanged or that are oxidatively metabolized (with corrections for metabolic capacity), it has been more challenging for compounds excreted primarily as conjugates in bile. (S)-10, 11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[ a, d]cycloheptene-10-acetic acid (SB-265123) is a novel alphavbeta3 ("vitronectin receptor") antagonist. In this study, the in vivo pharmacokinetics and in vitro plasma protein binding of SB-265123 were examined in four species: mice, rats, dogs, and monkeys. In monkeys and dogs, SB-265123 exhibited moderate clearance, whereas low clearance (<20% hepatic blood flow) was observed in the rat, and high clearance (>70% hepatic blood flow) was seen in the mouse. The concentration-time profiles indicated the possibility of enterohepatic recirculation; subsequent studies in bile duct-cannulated rats demonstrated extensive biliary excretion of an acyl-glucuronide of SB-265123. In allometric scaling to predict the disposition of SB-265123 in humans, various standard correction factors were applied, including protein binding, maximum lifespan potential, and brain weight; each failed to produce adequate interspecies scaling of clearance (r(2) < 0.72). Consequently, a novel correction factor incorporating bile flow and microsomal UDP-glucuronosyltransferase activity in each species was applied, demonstrating substantial improvement in the correlation of the allometric plot (r(2) = 0.96). This study demonstrates a novel allometric correction that may be applicable to compounds that undergo conjugation and biliary excretion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0090-9556(24)14923-9

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 39

Metadata

Authors
Ward, K. W., Azzarano, L. M., Bondinell, W. E., Cousins, R. D., Huffman, W. F., Jakas, D. R., Keenan, R. M., Ku, T. W., Lundberg, D., Miller, W. H., Mumaw, J. A., Newlander, K. A., Pirhalla, J. L., Roethke, T. J., Salyers, K. L., Souder, P. R., Stelman, G. J., & Smith, B. R.
Venue
Drug Metabolism and Disposition
Publisher
Elsevier BV
Published
1999-11
Volume
27
Issue
11
Pages
1232-1241
ISSN
0090-9556 (ISSN-L)
OpenAlex
W2198743295
Cited by
39
References
5
FWCI
2.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Pharmacokinetics and Interspecies Scaling of a Novel Vitronectin Receptor Antagonist. https://app.cochat.ai/papers/10.1016/s0090-9556(24)14923-9
The paper
Ward, K. W., Azzarano, L. M., Bondinell, W. E., Cousins, R. D., Huffman, W. F., Jakas, D. R., Keenan, R. M., Ku, T. W., Lundberg, D., Miller, W. H., Mumaw, J. A., Newlander, K. A., Pirhalla, J. L., Roethke, T. J., Salyers, K. L., Souder, P. R., Stelman, G. J., & Smith, B. R. (1999). Preclinical Pharmacokinetics and Interspecies Scaling of a Novel Vitronectin Receptor Antagonist. Drug Metabolism and Disposition. https://doi.org/10.1016/s0090-9556(24)14923-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.